Yoshimasa et al. also report that humoral factors, such as hepatocyte growth factor (HGF) and EVs derived from MSCs, show potential as therapeutic agents for mitigating the remaining risks associated with atherosclerosis [183]. This evidence concerns the gene HGF and atherosclerosis.